Bruker-Novacyt, PerkinElmer launch COVID-19 diagnostics; plus Nuclein speeds development of at-home test

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

New COVID-19 diagnostics were launched in Europe and the U.S. on Tuesday, while another company is speeding up development of an at-home PCR test.

Bruker Corp. (NASDAQ:BRKR) announced the European launch of a COVID-19 test from Primerdesign Ltd., a Novacyt S.A. (LSE:NCYT; Euronext:ALNOV) subsidiary. The real-time PCR test from Primerdesign’s genesig platform is to be used in conjunction with the GenoXtract automated genome extraction device and associated kits from Bruker subsidiary Bruker-Hain Diagnostics. Bruker has distribution rights for the PCR test, which has a CE-IVD mark.

Stateside, FDA granted an emergency use authorization (EUA) to PerkinElmer Inc. (NYSE:PKI) for its New Coronavirus RT-PCR test. CLIA-certified labs may run the test.

Additionally, Nuclein LLC announced plans to accelerate development and commercialization of its at-home Hand-Held PCR Test, which would give results within one hour. The company plans to launch the test by fall 2020.

Further analysis of the coronavirus crisis can be found at

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers